Your session is about to expire
← Back to Search
Unknown
3 mg HT-6184 QD for Normal Healthy Subjects
Phase 1
Waitlist Available
Led By Jesson Yeh, MD
Research Sponsored by Halia Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 weeks
Awards & highlights
Study Summary
This trial is testing a new drug to see if it is safe and works as intended. They will give it to healthy volunteers at different doses to see what happens.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 6 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of abnormal laboratory test results
Incidence of adverse events administered as single oral doses at escalating dose levels in healthy volunteer subjects.
Incidence of treatment-emergent clinically abnormal electrocardiogram (ECG)
+1 moreSecondary outcome measures
Apparent clearance (CL/F)
Apparent volume of distribution at steady state (Vss/F)
Area under the plasma concentration-time curve (AUC0-24)
+6 moreTrial Design
16Treatment groups
Active Control
Placebo Group
Group I: 3 mg HT-6184 QDActive Control1 Intervention
Cohort 3 - 6 subjects x 3 mg HT-6184 QD on Day 1
Group II: 4 mg HT-6184 QDActive Control1 Intervention
Cohort 4 - 6 subjects x 4 mg HT-6184 QD on Day 1
Group III: 1 mg HT-6184 QD x 2 weeksActive Control1 Intervention
Cohort 5 - 6 subjects x 1 mg HT-6184 QD on Day 1-5, 8-12
Group IV: 2 mg HT-6184 QD x 2 weeksActive Control1 Intervention
Cohort 6 - 6 subjects x 2 mg HT-6184 QD on Day 1-5, 8-12
Group V: 3 mg HT-6184 QD x 2 weeksActive Control1 Intervention
Cohort 7 - 6 subjects x 3 mg HT-6184 QD on Day 1-5, 8-12
Group VI: 4 mg HT-6184 QD x 2 weeksActive Control1 Intervention
Cohort 8 - 6 subjects x 4 mg HT-6184 QD on Day 1-5, 8-12
Group VII: 1 mg HT-6184 QDActive Control1 Intervention
Cohort 1 - 6 subjects x 1 mg HT-6184 QD on Day 1
Group VIII: 2 mg HT-6184 QDActive Control1 Intervention
Cohort 2 - 6 subjects x 2 mg HT-6184 QD on Day 1
Group IX: 1 mg Placebo QDPlacebo Group1 Intervention
Cohort 1 - 2 subjects x placebo, QD on Day 1
Group X: 3 mg Placebo QDPlacebo Group1 Intervention
Cohort 3 - 2 subjects x placebo, QD on Day 1
Group XI: 4 mg Placebo QDPlacebo Group1 Intervention
Cohort 4 - 2 subjects x placebo, QD on Day 1
Group XII: 1 mg Placebo QD x 2 weeksPlacebo Group1 Intervention
Cohort 5 - 2 subjects x 1 mg placebo, QD on Day 1-5, 8-12
Group XIII: 2 mg Placebo QD x 2 weeksPlacebo Group1 Intervention
Cohort 6 - 2 subjects x 2 mg placebo, QD on Day 1-5, 8-12
Group XIV: 3 mg Placebo QD x 2 weeksPlacebo Group1 Intervention
Cohort 7 - 2 subjects x 3 mg placebo, QD on Day 1-5, 8-12
Group XV: 2 mg Placebo QDPlacebo Group1 Intervention
Cohort 2 - 2 subjects x placebo, QD on Day 1
Group XVI: 4 mg Placebo QD x 2 weeksPlacebo Group1 Intervention
Cohort 8 - 2 subjects x 4 mg placebo, QD on Day 1-5, 8-12
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
TKL Research, Inc.Industry Sponsor
19 Previous Clinical Trials
1,633 Total Patients Enrolled
Halia Therapeutics, Inc.Lead Sponsor
1 Previous Clinical Trials
80 Total Patients Enrolled
Jesson Yeh, MDPrincipal InvestigatorTKL Research, Inc.
1 Previous Clinical Trials
128 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger